Sanofi (SNY)
Health Care
Sanofi (SNY) is listed on Nasdaq, where its shares have traded since July 1, 2002. SentiSense covers Sanofi in the Health Care sector. Belén Garijo is its chief executive officer. The company reports 74,846 employees, and its corporate website is www.sanofi.com.
About Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 705 institutions reported holding SNY, with 188.9 million shares worth $8.1 billion in aggregate. The largest reported holders were Dodge & Cox, Morgan Stanley and Fisher Asset Management. Of the 5 largest reported holders, 1 added shares and 4 reduced their positions during the quarter.
More on SNY
- SNY sentiment: whether news and social coverage of Sanofi leans bullish or bearish, and the stories driving it.
- SNY ownership: all 705 reporting institutions, plus insider and congressional trades.
- SNY financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Sanofi: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Sanofi do?
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases.
What sector is SNY in?
SentiSense classifies Sanofi in the Health Care sector.
Where does SNY stock trade?
Sanofi (SNY) is listed on Nasdaq, where its shares have traded since July 1, 2002.
Who is the CEO of Sanofi?
Belén Garijo is the chief executive officer of Sanofi.